NASDAQ · PMN
Healthcare · Biotechnology
$14.86
Up+$0.07 (+0.47%)
Updated Aug 15, 2026, 7:36 PM
SID Score
4.8/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
PMN does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
The latest Smart Investors Daily articles mentioning PMN.
PMN research
Company profile and research snapshot.
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 14, 2026 | Guggenheim | Buy | — |
| Jul 29, 2026 | Guggenheim | Buy | — |
| Jul 28, 2026 | Chardan Capital | Buy | — |
| Jul 27, 2026 | Chardan Capital | Buy | — |
| Jul 8, 2026 | Roth Capital | Buy | — |
No generated briefing is available yet.
Benzinga · Aug 13, 2026
ProMIS Neurosciences (NASDAQ:PMN) reported quarterly losses of $(1.28) per share which beat the analyst consensus estimate of $(1.38) by 7.25 percent. This is a 82.34 percent increase over losses of $(7.25) per share
Benzinga · Jul 29, 2026
Guggenheim analyst Eddie Hickman maintains ProMIS Neurosciences (NASDAQ:PMN) with a Buy and raises the price target from $35 to $69.
Benzinga · Jul 28, 2026
ProMIS Neurosciences announced positive interim Phase 1b trial data for its Alzheimer's drug candidate PMN310, showing zero ARIA-E.
Benzinga · Jul 28, 2026
Chardan Capital analyst Keay Nakae maintains ProMIS Neurosciences (NASDAQ:PMN) with a Buy and raises the price target from $20 to $33.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning PMN.
